Side-by-side · Research reference
AdipotidevsPancragen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED15/49 cited
BAnimal-StrongHUMAN-REVIEWED23/39 cited
Adipotide
Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only
IV · Systemic · Preclinical Protocols OnlyHossen 2013
01Mechanism of Action
Parameter
Adipotide
Pancragen
Primary target
Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Pathway
CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Downstream effect
Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Feedback intact?
N/A — Direct apoptotic mechanism, non-hormonal
Yes — preserves physiological glucose-insulin response
Origin
Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Antibody development
—
—
02Dosage Protocols
Parameter
Adipotide
Pancragen
Animal dose (mouse)
Low dose (not specified in abstract)Hossen 2013
Systemic injection in diet-induced obesity (DIO) models.Hossen 2013
—
Evidence basis
Preclinical animal models only
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Human data
None — no clinical trials reported
—
Primate dose (rhesus macaque)
—
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
Effective concentration (in vitro)
—
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
Diabetes model
—
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
03Metabolic / Fat Loss Evidence
Parameter
Adipotide
Pancragen
Primary fat target
White adipose tissue (all depots)
—
Body weight reduction
Significant reduction in DIO miceHossen 2013
Absolute values not provided in abstract.
—
Leptin levels
Significant decrease
Parallel to adipose mass reduction.
—
Effect on adipocytes
Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013
—
Ectopic fat
Reduction in ectopic fat depositionHossen 2013
Marker of dysfunctional adipose tissue / metabolic syndrome.
—
Species tested
Obese rhesus monkeys, DIO mice
—
Human translation
Unknown — no clinical trials
—
04Side Effects & Safety
Parameter
Adipotide
Pancragen
Safety profile
Unknown — preclinical data only
—
Vascular selectivity
Targets adipose vasculature; off-target vascular effects unknown
—
Apoptotic mechanism risk
Pro-apoptotic payload may affect unintended tissues if selectivity incomplete
—
Kidney / liver toxicity
Not reported in available data
—
Immunogenicity
Not assessed in available data
—
Reported adverse events
—
None documented in primate studies
Human safety data
—
No published human trials; clinical use limited to Russian gerontology protocols
Absolute Contraindications
Adipotide
- ·Human use — not approved, no clinical safety data
Pancragen
—Relative Contraindications
Adipotide
- ·Any condition requiring intact adipose-tissue vascularisation
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
05Administration Protocol
Parameter
Adipotide
Pancragen
1. Route
Intravenous injection (systemic) in preclinical models. No human protocols exist.
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
2. Formulation
Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
3. Preclinical dosing
Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013
No specific timing constraints documented. Administered once daily in primate protocols.
4. Storage
Not specified — likely requires peptide-grade lyophilised storage and reconstitution.
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014